An interventional study of TECNIS Toric II (ZCU) and AcrySof IQ Toric in Cataract, sponsored by Jin Yang. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Jin Yang · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Cataract with a site in China — 39 open to participants now, 49 under way, none of them phase 3. Cataract · China.
Among the 184 studies in Cataract with a site in China, this one is the 12th largest by planned enrollment of the 111 interventional ones that give a count, is one of 15 that started in 2025, is one of 104 with no phase, reaches primary completion later than 30 of the 48 other live ones, and was the 166th registered.
1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.
Browse Cataract studies →39 of the 184 studies in Cataract with a site in China are open now. Recruiting first, the newest first:
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 18–90
Nanfang Hospital, Southern Medical University · Sites in China
Ages 40–85
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–90
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 50–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 15 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 90 across the 111 interventional studies, 120 across the 73 observational. Of the 80 that completed or were terminated, 9 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 184 have an industry lead sponsor. The 10 most frequent:
Jin Yang is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
Jin Yang has 6 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
7 of the studies in Cataract with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07713069Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOCT-PRO Model vs. Clinicians: Cataract Surgery Outcome Prediction | 2026-11-30 |
| NCT02182921Evidence Based Cataract Study GroupEvaluation of Cataract Surgery Outcome | 2026-12 |
| NCT07550907Zhongshan Ophthalmic Center, Sun Yat-sen UniversityThe Impact of Surgical Procedures on Postoperative Outcomes in Cataract Phacoemulsification and Analysis of Related Factors | 2026-12-31 |
| NCT07733154The Hong Kong Polytechnic UniversityAI-Driven IOL Prediction Using SS-OCT Biometry | 2027-03-20 |
| NCT07126470Zhongshan Ophthalmic Center, Sun Yat-sen UniversityImpact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients | 2027-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 184 studies in Cataract with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective comparative cohort study evaluates and compares postoperative rotational stability and time-course dynamics of three commercially available toric intraocular lenses (TECNIS Toric II [ZCU], AcrySof IQ Toric, and AT TORBI 709M) after phacoemulsification cataract surgery. Rotation is quantified by registering postoperative retroillumination photographs to the end-of-surgery baseline using iris/scleral landmarks, with follow-up at postoperative day 1, day 3, week 1, week 2, month 1, and month 3. Associations between rotational outcomes and ocular biometric parameters are analyzed using linear mixed-effects models to inform individualized IOL selection and perioperative management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm receive implantation of the TECNIS Toric II (ZCU) intraocular lens during standard phacoemulsification cataract surgery.
Device: TECNIS Toric II (ZCU)
Participants randomized to this arm receive implantation of the AcrySof IQ Toric intraocular lens during standard phacoemulsification cataract surgery.
Device: AcrySof IQ Toric
Participants randomized to this arm receive implantation of the AT TORBI 709M intraocular lens during standard phacoemulsification cataract surgery.
Device: AT TORBI 709M
Using TECNIS Toric II (ZCU) intraocular lens during standard phacoemulsification cataract surgery.
Using AcrySof IQ Toric intraocular lens during standard phacoemulsification cataract surgery.
Using the AT TORBI 709M intraocular lens during standard phacoemulsification cataract surgery.
Absolute rotational misalignment of toric intraocular lens (IOL) measured in degrees
Absolute rotation of the implanted toric intraocular lens (IOL) relative to the intended axis, measured in degrees. Rotation will be quantified by registering postoperative retroillumination images to the end-of-surgery baseline frame using iris or scleral landmarks. The absolute rotation angle will be calculated for each follow-up visit.
Time frame: Postoperative day 1, day 3, week 1, week 2, month 1, and month 3.
Uncorrected and corrected distance visual acuity (UDVA and CDVA)
Uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) measured using a standardized logarithm of the minimum angle of resolution (logMAR) visual acuity chart during follow-up.
Time frame: postoperatively on 1 day, 3 days, 1 week, 2 weeks, 1 month and 3 months
Postoperative residual refractive astigmatism measured in diopters
Residual refractive astigmatism measured by manifest refraction during follow-up visits and reported in diopters (D).
Time frame: Postoperative day 1, day 3, week 1, week 2, month 1, and month 3.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Oct 2026, 21 months after the start.
Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 21 months is above that.
Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jin Yang